Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Hematologic Malignancies
•
Medical Oncology
•
Myelodysplastic Syndromes
•
Hematology
How do you sequence luspatercept and imetelstat for treatment of anemia in MDS?
Related Questions
Would you hold off iron chelation in a transfusion dependent MDS patient with elevated ferritin but with negative iron stain on the bone marrow?
How do you manage high-risk MDS IB2 patients on HMA and venetoclax who develop an acute stroke requiring antiplatelet therapy?
How do you manage a patient with low risk MDS who achieves transfusion independence with luspatercept but continues to have fatigue?
How do you approach management for CCUS with severe cytopenias?
How do you approach severe anemia and thrombocytopenia in an elderly patient whose bone marrow biopsy shows hypercellular marrow with mild dysplasia in erythroid and megakaryocytic lineage but normal cytogenetics and a negative NGS panel?
What is your approach for choosing between Imetelstat and Luspatercept in managing MDS related anemia?
How do you approach c-KIT mutated, core binding factor (CBF) AML?
What are your top takeaways in Hematology from ASCO 2025?
How would you treat a patient with selective IgM deficiency on IVIG infusions with a new diagnosis of CLL?
If a bone marrow biopsy reveals mast cell leukemia, would you consider treating with avapritinib?
